Evidence map›Paper›PMID 42638855›Full record

ArticleFrontiers in oncology2026

Exploiting machine-learning models with DCE-MRI radiomics for breast cancer molecular subtyping.

Yang Lou, Liang Zhao

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yang LouDepartment of Radiology, Affiliated Hospital of Hebei University, Baoding, Hebei, China.
Liang ZhaoDepartment of Radiology, Affiliated Hospital of Hebei University, Baoding, Hebei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is a heterogeneous disease, and accurate preoperative identification of molecular subtypes is essential for guiding individualized treatment and prognostic evaluation. However, histopathological assessment, the current gold standard, is invasive and limited by intratumoral heterogeneity, underscoring the need for reliable noninvasive alternatives. Radiomics based on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has shown promise for molecular subtype prediction; nevertheless, the optimal radiomic features for automated molecular classification remain to be fully elucidated. To address this gap, this study aims to identify optimal DCE-MRI radiomic features and to develop radiomics-based machine learning models for predicting breast cancer molecular subtypes. Specifically, regions of interest were manually delineated on DCE-MRI images for feature extraction, followed by feature selection to identify the most informative radiomic parameters. Four machine learning classifiers (RF, SVM, LR, GBDT) were then constructed to predict five molecular subtypes of breast cancer. The experimental results demonstrate that the optimized DCE-MRI-based radiomics model effectively predicts breast cancer molecular subtypes. In particular, the gradient boosting decision tree (GBDT) model combined with rigorous feature selection shows high predictive performance, highlighting its strong potential for noninvasive, accurate, and clinically applicable molecular classification of breast cancer.

Indexed as

breast cancer molecular subtypingDCE-MRI–based radiomics modelfeature selectionmulti-class classification modelROI feature extraction

Identifiers

PMID42638855
PMCPMC13500262

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.